Blood-Based Biomarkers for Pancreatic Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to develop a simple blood test to detect pancreatic cancer early and monitor treatment effectiveness. It involves collecting blood samples (also known as phlebotomy or venipuncture) from various groups, including those with advanced pancreatic cancer, benign pancreatic conditions, and healthy individuals. People diagnosed with pancreatic issues, such as chronic pancreatitis or benign cysts, who are willing to provide blood, tissue, or tumor samples, may be suitable candidates. As an unphased trial, this study offers participants the chance to contribute to groundbreaking research that could lead to early detection and improved treatment monitoring for pancreatic cancer.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Why are researchers excited about this trial?
Researchers are excited about this trial because it aims to uncover new blood-based biomarkers for pancreatic cancer, which is a fresh approach compared to traditional methods like imaging and invasive biopsies. This method could potentially offer a less invasive, quicker, and more convenient way to detect and monitor pancreatic cancer progression. By analyzing blood, cyst fluid, and tumor tissue, scientists hope to improve early detection and personalized treatment strategies, potentially leading to better outcomes for patients with pancreatic conditions.
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline
Blood specimens are drawn at study baseline for all cohorts
Treatment Monitoring
For patients with locally advanced or metastatic PDAC, blood is collected pre-treatment, after first chemotherapy cycle, every 8-12 weeks during treatment, and at disease progression
Follow-up
For patients with acute or chronic pancreatic conditions, blood specimens are drawn every 6-12 months
What Are the Treatments Tested in This Trial?
Interventions
- Blood Draw
- Cyst Fluid
- Tumor Tissue Collection
How Is the Trial Designed?
4
Treatment groups
Experimental Treatment
For patients with locally advanced or metastatic PDAC, blood will be collected pre-treatment initiation (baseline), after first chemotherapy cycle, every 8-12 weeks while under treatment to coincide with restaging CT scan and at time of disease progression.
For normal controls, blood specimens will be drawn once at study baseline.
For patients with chronic pancreatitis, IPMN, or cysts, blood specimens will be drawn every 6-12 months.
For patients with acute pancreatitis, blood specimens will be drawn at the time of acute pancreatitis and every 6-12 months thereafter
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor
Weill Medical College of Cornell University
Collaborator
Weizmann Institute of Science
Collaborator
Sheba Medical Center
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.